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Summary
Background Substantial progress has been made in reducing the burden of malaria in Africa since 2000, but those 
gains could be jeopardised if the COVID-19 pandemic affects the availability of key malaria control interventions. The 
aim of this study was to evaluate plausible effects on malaria incidence and mortality under different levels of 
disruption to malaria control.
Methods Using an established set of spatiotemporal Bayesian geostatistical models, we generated geospatial 
estimates across malaria-endemic African countries of the clinical case incidence and mortality of malaria, 
incorporating an updated database of parasite rate surveys, insecticide-treated net (ITN) coverage, and effective 
treatment rates. We established a baseline estimate for the anticipated malaria burden in Africa in the absence of 
COVID-19-related disruptions, and repeated the analysis for nine hypothetical scenarios in which effective treatment 
with an antimalarial drug and distribution of ITNs (both through routine channels and mass campaigns) were 
reduced to varying extents.
Findings We estimated 215·2 (95% uncertainty interval 143·7–311·6) million cases and 386·4 (307·8–497·8) thousand 
deaths across malaria-endemic African countries in 2020 in our baseline scenario of undisrupted intervention 
coverage. With greater reductions in access to effective antimalarial drug treatment, our model predicted increasing 
numbers of cases and deaths: 224·1 (148·7–326·8) million cases and 487·9 (385·3–634·6) thousand deaths with a 
25% reduction in antimalarial drug coverage; 233·1 (153·7–342·5) million cases and 597·4 (468·0–784·4) thousand 
deaths with a 50% reduction; and 242·3 (158·7–358·8) million cases and 715·2 (556·4–947·9) thousand deaths with 
a 75% reduction. Halting planned 2020 ITN mass distribution campaigns and reducing routine ITN distributions by 
25%–75% also increased malaria burden to a total of 230·5 (151·6–343·3) million cases and 411·7 (322·8–545·5) 
thousand deaths with a 25% reduction; 232·8 (152·3–345·9) million cases and 415·5 (324·3–549·4) thousand deaths 
with a 50% reduction; and 234·0 (152·9–348·4) million cases and 417·6 (325·5–553·1) thousand deaths with a 
75% reduction. When ITN coverage and antimalarial drug coverage were synchronously reduced, malaria burden 
increased to 240·5 (156·5–358·2) million cases and 520·9 (404·1–691·9) thousand deaths with a 25% reduction; 
251·0 (162·2–377·0) million cases and 640·2 (492·0–856·7) thousand deaths with a 50% reduction; and 
261·6 (167·7–396·8) million cases and 768·6 (586·1–1038·7) thousand deaths with a 75% reduction.
Interpretation Under pessimistic scenarios, COVID-19-related disruption to malaria control in Africa could almost 
double malaria mortality in 2020, and potentially lead to even greater increases in subsequent years. To avoid a 
reversal of two decades of progress against malaria, averting this public health disaster must remain an integrated 
priority alongside the response to COVID-19.
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Introduction
The ongoing COVID-19 pandemic is the most sustained, 
disruptive, and lethal infectious disease outbreak since 
the influenza pandemic of 1918. As of late August, 2020, 
the reported case incidence of COVID-19 in Africa 
remains modest compared with many regions worldwide; 
however, cases have been detected in most countries and 
incidence in some places is increasing rapidly. Countries 
in Africa are mounting a concerted public health response 
to limit the potential extent of COVID-19 morbidity 
and mortality on the continent,1,2 drawing on decades of 
experience in large-scale public health activities to 
mitigate the burden of endemic and epidemic infectious 
diseases. Compared with the responses to COVID-19 in 
high-income nations, however, the measures taken in 
Africa come amid the backdrop of more acute health-
system resource limitations3 and persistently higher 
morbidity and mortality from other infectious diseases.4,5 
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As such, on top of concerns about the disease itself, alarm 
is growing about the broader health, economic, and 
societal effects of the measures imposed to slow the 
spread of COVID-19. Of particular concern is the possible 
disruption to efforts to control other endemic diseases 
that pose ongoing threats.
Since 2000, enormous progress has been made 
in reducing the burden of malaria in Africa.6,7 The 
development of effective tools to reduce transmission 
by targeting the vector (such as the distribution of 
insecticide-treated nets (ITNs) and the spraying of structures 
with long-lasting insecticides) and the parasite (through 
reliable point-of-care diagnostic testing and effective 
antimalarial drugs), coupled with strengthening health 
systems and surveillance, have collectively saved millions of 
lives over the past decade.7 Until malaria transmission is 
interrupted altogether, however, these efforts merely 
suppress the disease. In the absence of a long-lasting 
vaccine, and because the underlying environmental 
suitability for Plasmodium spp transmission remains high,8 
malaria is likely to resurge rapidly if intervention coverage 
falters.9,10 This issue is especially pressing in places where 
levels of human population immunity are waning because 
of high intervention coverage.
The COVID-19 epidemic in Africa threatens malaria 
control in numerous ways. First, already-fragile health-
system capacity risks being overwhelmed, meaning access 
to primary care for routine case management and the 
availability of hospitalisation for severe malaria could 
decrease sharply. Second, delivery of malaria control 
across the continent relies on a substantial workforce 
distributed across multiple sectors, including front-line 
health workers, health-system administrators, and logistic 
and field personnel orchestrating community-based 
intervention delivery. Widespread absenteeism due to 
illness, restrictions on movement, or diversion to the 
COVID-19 response means that this workforce could be 
critically disrupted. Third, supply chains that allow 
malaria control commodities such as drugs, bednets, 
rapid diagnostic test kits, and insecticide to be manu-
factured, procured, and delivered internationally and 
within Africa will be jeopardised by movement res-
trictions. Fourth, malaria control relies heavily on the 
decision making of patients and their families, including 
choosing to leave their homes to seek care for febrile 
children and receiving ITNs delivered at antenatal clinics 
or schools. Decisions such as these will be affected 
by additional illness, risk perception, or movement 
restrictions, all of which could jeopardise the provision 
and use of key malaria interventions.
Recognition of the threat posed to malaria control by 
COVID-19 has been widespread,11 and there is an urgent 
need to properly contextualise these threats amid rapidly 
evolving global health priorities. Doing so will require 
Research in context
Evidence before this study
Decades of data collection and recent modelling efforts have 
shown declining malaria burden in Africa since 2000. 
Past research by the Malaria Atlas Project, in collaboration with 
WHO, has been used to estimate the proportion of malaria cases 
that have been prevented by widespread use of antimalarial 
interventions. The effects of and the proposed response to the 
COVID-19 pandemic pose an immediate threat to distribution 
of insecticide-treated nets (ITNs) and access to effective 
treatment with antimalarial drugs, the two most important 
components of malaria control in Africa. We searched PubMed 
on June 24, 2020, using the search terms [“COVID-19” OR 
“SARS-CoV-2” OR “2019-nCoV” OR “coronavirus”] AND malaria, 
for articles published in English, with no date restrictions. Of the 
97 articles returned, three were commentary or policy pieces 
that highlighted the possible indirect effect of the COVID-19 
pandemic on malaria control and burden but did not include 
quantitative analyses. The remaining 94 articles were not 
relevant. Plausible effects of the COVID-19 pandemic on malaria 
interventions and the resulting implications for malaria burden 
have not previously been assessed through quantitative 
analyses.
Added value of this study
Using a range of plausible reduction scenarios for ITN 
distribution and provision of antimalarial drug treatment, 
we estimated the possible additional malaria-attributable 
morbidity and mortality across malaria-endemic African 
countries in 2020 relative to a baseline in which intervention 
deployment is unhindered. The regional-level and national-
level results show geographically varying implications of 
reduced intervention coverage, reflecting differences in 
epidemiology and pre-pandemic intervention status within 
countries. For example, areas that had mass ITN distribution 
campaigns in 2019 were less affected in our scenarios because 
of the continued use of the nets already present in 
households.
Implications of all the available evidence
Decreased access to ITNs and antimalaria drugs, two key 
malaria interventions, would lead to potentially catastrophic 
increases in malaria morbidity and, in particular, mortality 
within Africa. By enumerating the potential outcomes of 
reduced coverage under a range of scenarios, we provide 
public health policy makers in malaria-endemic countries 
with additional information to consider when planning their 
COVID-19 responses. Where possible, to limit disease and 
death overall, future planning at international and national 
levels should consider the potential for catastrophic increases 
in malaria when designing COVID-19 mitigation strategies.
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granular information with which to compare the relative 
threats posed by the spatially varying deterioration of 
malaria interventions. In this Article, we focus on the 
two primary tools for reducing malaria transmission and 
disease burden in Africa: ITNs and effective treatment 
with antimalarial drugs. We use the data and analytical 
architectures of the Malaria Atlas Project,6,7,12,13 Global 
Burden of Disease Study (GBD),14 and World Malaria 
Report15 to evaluate scenarios of declining population 
coverage of these interventions and their consequences 
for case incidence and malaria mortality.
Concerns over the effect of COVID-19 on malaria in 
Africa prompted WHO to issue an urgent request for 
analyses characterising the magnitudes of potential 
resur gences in cases and deaths from malaria. This 
research was a direct response to this call for action, and 
our results have been incorporated into a newly released 




We analysed the potential effect of COVID-19 on malaria 
by combining the following components (figure 1): 
(1) up-to-date geospatial estimates of contemporary ITN 
and antimalarial drug coverages; (2) varied scenarios of 
deteriorating coverage for each intervention separately 
and in combination; (3) a Bayesian geostatistical space–
time model to predict infection prevalence at a 5 × 5 km 
spatial resolution that incorporates ITN and antimalarial 
drug coverages as model covariates; (4) an established 
natural history model used to infer age-specific 
clinical incidence rates from malaria prevalence; and 
(5) an established geospatial model to predict malaria-
attributable mortality given the incidence rate and 
effective treatment rates, calibrated to malaria-specific 
and an all-cause mortality envelopes provided by 
GBD 2019.14 The results of this analysis were aligned 
with those from the 2019 World Malaria Report15 to 
maximise the interpretability of the results and the 
comparability between our findings and established 
benchmarks. Our analysis included all malaria-endemic 
countries of Africa with the exception of Botswana, 
Comoros, Cape Verde, Djibouti, Eswatini, and São Tomé 
and Príncipe, where very low transmission and small 
numbers of cases and deaths meant analysis was not 
appropriate. We summarise each model component 
below, with further technical details provided in the 
appendix.
ITN coverage and deterioration scenarios
Realistically estimating the public health effect of dis-
tributions on ITN coverage requires an explicit accoun ting 
of net procurement, distribution, and retention and use by 
Figure 1: Simplified methodological flow chart
Orange rectangles represent input datasets, some of which are modelled results from preceding analyses. Blue rectangles represent predefined process steps for which we supplied new data. 
Green rectangles are new conversions added to the production chain for this project. Purple rectangles are the results of the analysis. GBD=Global Burden of Disease Study. ITN=insecticide-treated net. 
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households. We calculated ITN coverage (defined as the 
proportion of people sleeping under an ITN) for 2000–20 
using an adaptation of an established mixed-modelling 
framework.7,17 The model first uses a Gibbs sampler-based 
mechanistic model to triangulate data on ITN stock within 
countries, distributions, and ownership to produce 
estimates of country-specific ITN access and retention 
rates. These national-level indicators are then disaggregated 
spatially and converted to coverage via a series of 
spatiotemporal regressions. Models were calibrated to data 
on ITN stock from the Alliance for Malaria Prevention’s 
Net Mapping Project,18 data on ITN distributions from 
national malaria control programmes and the African 
Leaders Malaria Alliance project, and data on ITN 
ownership from 156 nationally representative surveys 
conducted and disseminated by the Demographic and 
Health Surveys (DHS) Program.19 For projected 2020 
distribution campaigns, we used data on planned timing 
and distribution size (number of nets) from the African 
Leaders Malaria Alliance and the President’s Malaria 
Initiative Malaria Operational Plans.20
In almost every African country, ITNs are distributed 
on an ongoing basis via routine patient contacts with the 
health system, such as antenatal clinics and child 
immunisation centres, and sometimes additionally 
through schools. However, in most countries a larger 
proportion of ITNs are distributed directly to households 
via intermittent mass campaigns, usually every 2–4 years. 
An immediate risk is that mass campaigns planned for 
2020 will be cancelled in light of the many challenges 
imposed by COVID-19 in Africa. Meanwhile, broader 
supply chain, health-system, and behavioural obstacles 
are likely to diminish the capacity of routine distribution 
channels to deliver ITNs to populations in need. As such, 
we explored three counterfactual scenarios whereby 
planned mass campaign distributions ceased for 2020, 
while routine channels were reduced by 25%, 50%, or 
75% relative to the baseline scenario wherein all 
distributions proceeded as planned in 2020. In each 
scenario, we captured the fact that ITNs already present 
within households at the outset of 2020 will continue to 
offer waning protection in accordance with country-
specific retention rates. Therefore, countries with large 
distributions in 2019 are likely to be less affected by 
service disruptions than countries that were planning 
mass campaigns in 2020.
Antimalarial drug coverage and deterioration scenarios
We estimated the fraction of clinical malaria cases 
receiving effective treatment at a 5 × 5 km spatial resolution 
from 2000 to 2020. This model combines the fraction of 
children under 5 years of age who seek and receive 
treatment, the fractional use of antimalarial drug by 
antimalarial class, and the effectiveness of antimalarial 
drug by antimalarial class. Treatment seeking was 
modelled with use of an existing geospatial approach to 
estimate the fraction seeking care from national surveys 
on caregivers responses.21 This approach relied on the 
assumption that treatment seeking for fever in children 
under 5 years of age in malaria-endemic African countries 
adequately represents malaria-specific treatment seeking 
patterns for all age groups. Data on care-seeking behaviour 
and antimalarial drug access from DHS Program 
surveys,19 Malaria Indicator Surveys,22 and Multiple 
Indicator Cluster Surveys,23 were used in a generalised 
fractional regression model to estimate the country-year-
specific fraction of malaria care seekers receiving different 
classes of antimalarial drugs. A geostatistical model was 
applied to site-specific clinical efficacy data compiled 
by the Worldwide Antimalarial Resistance Network24 to 
create drug-country-year-specific estimates of treatment 
effectiveness for those receiving antimalarials, while also 
incorporating reduction factors for drug quality and 
patient non-adherence to drug use protocols. These three 
components were combined to yield an overall estimate of 
the fraction of malaria cases receiving effective treatment. 
Because no data were yet available for 2020, we assumed 
the 2020 baseline scenario would correspond to coverage 
levels in 2019.
We then imposed three simple coverage reduction 
scenarios whereby the proportion of patients with 
malaria treated with antimalarial drugs was reduced 
25%, 50%, or 75% from the baseline level. Because nearly 
all antimalarial drug access was by routine channels, 
there was no equivalent of a mass campaign to consider 
other than seasonal malaria chemoprevention, which we 
did not include in this analysis. We thus explored simple 
levels of reduction in antimalarial drug coverage, 
recognising that, in reality, deteriorations in access to 
treatment would occur in a highly spatially heterogenous 
way, reflecting local systems of drug supply and the 
varying effects of the COVID-19 outbreak.
Spatiotemporal estimation of infection prevalence and 
intervention impact
A Bayesian geostatistical framework has been presented 
previously for estimating malaria infection prevalence and 
intervention impact.7 The updated response data consist 
of 53 770 observations of community-level Plasmodium 
falciparum parasite rate (PfPR)—ie, the proportion of 
the population carrying the parasite—in Africa from 
2000 to 2020. These observations result from parasitaemia 
tests conducted for 3·97 million individuals, age-
standardised to 2–10-year-old children (PfPR2–10),25 and are 
collated by the Malaria Atlas Project on an ongoing basis 
from the DHS Program, national Malaria Indicator 
Surveys, and the published literature, using systematic 
approaches described previously.26 P falciparum was the 
focus of this research because this species is responsible 
for the majority of malaria infections and deaths in Africa. 
The prevalence model generated annual realisations of 
PfPR2–10 for each 5 × 5 km pixel across malaria-endemic 
Africa. By triangulating data on PfPR, ITNs, and anti-
malarial drugs, along with a suite of environmental 
For more on the African Leaders 
Malaria Alliance see https://
alma2030.org/
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covariates,27 we estimated the impact of each intervention 
on PfPR2–10 and inferred the pre-intervention transmission 
intensity. The fitted model was then used to predict a 
baseline PfPR2–10 in 2020 using the pre-pandemic ITN and 
antimalarial drug coverage estimates, thus reflecting 
2020 infection prevalence in the absence of COVID-19 
disruptions. We then derived counterfactual versions for 
each of the scenarios of deteriorating ITN and antimalarial 
drug coverage. For each scenario, a set of 100 realisation 
surfaces was generated and propagated through the 
incidence and mortality models described below. Results 
were converted into population-weighted estimates by 
intersecting the realisations with gridded population 
surfaces. Finally, we summarised mean values and 95% 
uncertainty intervals (UIs) for each nation and for all of 
malaria-endemic Africa from the set of realisations, while 
also calculating percentage change estimates relative to 
the baseline means.
Estimation of clinical incidence and malaria mortality
Each scenario of PfPR2–10 in 2020 was used to generate a 
corresponding estimate of clinical incidence rate using 
an established natural history model.28 An existing 
approach6,13 was then used to infer corresponding levels of 
malaria-attributable mortality for each clinical incidence 
scenario. The mortality estimation model relied on cause 
of death data and an all-cause mortality envelope, both of 
which were obtained from GBD 2019 data.14 This 
approach produces spatially heterogeneous surfaces of 
case fatality rate for untreated malaria for each modelled 
Figure 2: Estimated effect of deteriorating malaria control in Africa
For each of nine scenarios of disrupted intervention coverage (table), we estimated the resulting number of malaria cases (A) and deaths (C), and the relative 
increases in cases (B) and deaths (D). Percentage reductions are relative to the baseline scenario of undisrupted antimalarial drug treatment and ITN distribution 
(as delivered via mass campaign and routine distributions). Error bars are 95% uncertainty intervals. ITN=insecticide-treated net. *ITN reduction scenarios consist of 
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year. Untreated incidence was derived by multiplying 
the incidence surfaces by one minus antimalarial drug 
coverage, and the resulting grid was multiplied by the 
case fatality rate surface to yield a 5 × 5-km map of 
deaths due to malaria. All mortality estimates were 
proportionately rescaled to align our baseline values with 
the World Malaria Report estimates for the year 2018.15 
The mortality estimation framework thus relied on the 
effective treatment with an antimalarial drug in two 
ways: as a covariate in the PfPR2–10 model and for cleaving 
incidence into treated and untreated cases. Antimalarial 
drug coverage not only reduces incidence by reducing 
the duration that infected individuals contribute to 
onward transmission, but also reduces deaths by 
reducing the number of uncomplicated cases that 
develop severe, life-threatening malaria.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The counterfactual analyses indicated that reducing the 
coverage of key malaria interventions would substantially 
affect the number of malaria cases in Africa relative 
to the baseline number of 215·2 (95% UI 143·7–311·6)
million (figure 2A, B; table). Notably, reducing anti-
malarial drug coverage would have a greater impact on 
malaria incidence than decreasing ITN coverage. For 
example, in our model, a 75% drop in antimalarial drug 
coverage (scenario 3) increased the case count by 27·1 
(22·2–32·8) million, whereas a 75% drop in routine ITN 
distributions coincident with a complete cessation of 
mass ITN distributions (scenario 6) increased cases by 
18·8 (12·8–26·7) million. The combined effects of 75% 
reductions in both interventions (scenario 9) caused 
cases to increase by 46·4 (35·0–60·0) million.
The potential increase in malaria-attributable deaths 
as a result of the COVID-19 pandemic is a greater cause 
for concern than the potential increase in malaria cases. 
At baseline, with undisrupted intervention, we estimated 
386·4 (307·8–497·8) thousand malaria-attributable 
deaths in 2020. Although the modelled reductions in 
ITN coverage (scenarios 4–6) led to proportional 
increases in both cases and deaths, the effect of 
decreasing anti malarial drug coverage was more 
pronounced because of the role that effective treatment 
of malaria plays in preventing deaths from the disease 
(figure 2C, D; table). For example, even if ITN 
distributions in 2020 were unaffected by COVID-19, we 
estimated that a 75% reduction in antimalarial drug 
coverage (scenario 3) would increase deaths from 
malaria by 328·7 (311·6–350·2) thousand. Furthermore, 
the additive effect of reductions in both interventions 
(scenarios 7–9), which increased cases and also treated 
fewer of them, increased the number of deaths by 134·5 
(120·1–151·7) thousand with 25% reductions in both 
interventions, 253·7 (230·3–279·8) thousand with 50% 
reductions, and 382·1 (348·2–421·5) thousand with 75% 
reductions.
Malaria burden, intervention coverages, and case 
fatality rate varied spatially and were thus estimated 
using geospatial modelling approaches. This metho-
dological framework produced maps of malaria incidence 
and mortality with 5 × 5 km spatial resolution for each of 
the counterfactual scenarios. To better illustrate the 
effects of national-level policy decisions in response to 
COVID-19, we summarised and mapped outputs by 
country (figure 3, 4). These national-level results present 




















Baseline Yes ·· ·· 215·2 (143·7–311·6) ·· ·· 386·4 (307·8–497·8) ·· ··
Scenario 1 Yes ·· 25% 224·2 (148·7–326·8) 8·9 (7·4–10·5) 4·1% (3·4–4·9) 487·9 (385·3–634·6) 101·5 (97·1–106·5) 26·3% (25·1–27·6)
Scenario 2 Yes ·· 50% 233·1 (153·7–342·5) 17·9 (14·8–21·4) 8·3% (6·9–10·0) 597·4 (468·0–784·4) 211·0 (200·8–223·0) 54·6% (52·0–57·7)
Scenario 3 Yes ·· 75% 242·3 (158·7–358·8) 27·1 (22·2–32·8) 12·6% (10·3–15·2) 715·2 (556·4–947·9) 328·7 (311·6–350·2) 85·1% (80·6–90·6)
Scenario 4 No 25% ·· 228·4 (151·6–343·3) 13·2 (11·0–23·3) 6·1% (5·1–10·8) 410·0 (322·8–545·5) 23·6 (18·1–38·5) 6·1% (4·7–10·0)
Scenario 5 No 50% ·· 232·8 (152·3–345·9) 17·6 (11·9–24·9) 8·2% (5·5–11·6) 415·5 (324·3–549·4) 29·1 (19·8–41·3) 7·5% (5·1–10·7)
Scenario 6 No 75% ·· 234·0 (152·9–348·4) 18·8 (12·8–26·7) 8·7% (5·9–12·4) 417·6 (325·5–553·1) 31·1 (21·2–44·3) 8·1% (5·5–11·5)
Scenario 7 No 25% 25% 240·5 (156·5–358·2) 25·2 (18·4–33·1) 11·7% (8·6–15·4) 520·9 (404·0–691·9) 134·5 (120·1–151·7) 34·8% (31·1–39·2)
Scenario 8 No 50% 50% 251·0 (162·2–377·0) 35·8 (26·8–46·1) 16·6% (12·4–21·4) 640·2 (492·0–856·7) 253·7 (230·3–279·8) 65·7% (59·6–72·4)
Scenario 9 No 75% 75% 261·6 (167·7–396·8) 46·4 (35·0–60·0) 21·5% (16·3–27·9) 768·6 (586·1–1038·7) 382·1 (348·2–421·5) 98·9% (90·1–109·1)
Data in parentheses are 95% uncertainty intervals. All uncertainty estimates were derived at the pixel level from the set of realisations and then summarised for all malaria-endemic countries in Africa. Estimates 
are also represented graphically in figure 2.
Table: Baseline and counterfactual scenario estimates of malaria incidence and mortality for Africa
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a more nuanced picture than those at continental 
scale. Geographical patterns in the absolute effects on 
morbidity and mortality (figure 3 A, B) largely reflect the 
magnitude of underlying burden, such that countries 
with high transmission and high population—including 
Nigeria, DR Congo, and Mozambique—are predicted to 
yield the largest increases should malaria control falter. 
Patterns of relative impact (figure 3 C, D) are different, 
being additionally driven by current ITN and antimalarial 
drug coverage levels, variations in case fatality rate, and 
whether or not countries had a mass ITN distribution 
campaign scheduled for 2020. Figure 4 gives additional 
insight into the relative roles of disruption to different 
interventions in each country, particularly for the 
predicted effects on cases. Of the four countries with the 
largest predicted effects on cases, Nigeria and DR Congo 
are predicted to be the most impacted by disruptions 
to antimalarial drugs, whereas in Uganda and Côte 
d’Ivoire, disruptions to ITN distributions are more 
impactful. These differences reflect both the underlying 
Figure 3: Estimated effects of a 75% reduction in malaria control in Africa by country
Estimates are shown for scenario 9 (no mass distributions of insecticide-treated nets, and 75% reductions in routine insecticide-treated net distribution and 
antimalarial drug treatment, relative to undisrupted levels). Results are mapped for absolute increases in cases (A) and deaths (B), and relative increases in cases (C) 
and deaths (D). Countries shaded in grey were not included in the analysis. 
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transmission setting and the current status of those 
interventions in each country.
Cancelling mass ITN campaigns would have a sub-
stantial impact on 2020 ITN coverage in Africa, especially 
in those countries that have not had mass campaigns in 
several years (figure 5). South Sudan, for example, is 
scheduled to have its largest mass campaign in history in 
2020, increasing ITN coverage from 32·5% in 2019 to 
72·7% in 2020. In the absence of mass campaigns, 2020 
coverage is instead projected to decline to 16·0%, falling 
additionally to 12·3% if routine channels suffer a 75% 
decrease in capacity. South Sudan is one of the few 
countries in which reductions in ITN coverage alone are 
likely to have a larger impact than reductions in anti-
malarial drug coverage alone, with no 2020 mass campaign 
and a 25% reduction in routine ITN distribution 
causing an increase of 564·0 (277·1–968·1) thousand cases 
and 1167 (573–2003) deaths in our model. By contrast, a 
25% reduction in antimalarial drug coverage would 
increase cases by 13·0 (7·8–17·2) thousand and deaths by 
105 (94–113). Other countries likely to be affected more by 
reductions in ITN distribution than by declines in 
Figure 4: Estimated effects of deteriorating malaria control by intervention type and disruption level for the 20 most affected countries
Estimated increases in cases (A) and deaths (B) for each country given reductions of 25%, 50%, and 75% (vs undisrupted baseline levels) in ITN distribution and antimalarial drug treatment, separately 
and combined. Bars are cumulative such that bottom segment (lightest shading) represents a 25% reduction, the bottom two segment (light and intermediate shading) represent a 50% reduction, 
and the full height of the bar (light, intermediate, and dark shading) represent a 75% reduction. ITN=insecticide-treated net. *ITN reduction scenarios consist of cessation of all mass distribution 
campaigns in addition to a reduction in routine distribution by the percentage specified.
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antimalarial drug coverage include Benin, Côte d’Ivoire, 
Guinea-Bissau, and Chad, all of which have ambitious 
mass ITN campaigns planned for 2020. Tables of planned 
national-level ITN distributions and counterfactual results 
are provided in the appendix (pp 1–15).
Discussion
The intensity of COVID-19 outbreaks in African countries 
and the resulting effects on malaria incidence and 
mortality are inherently unpredictable. It is inevitable, 
however, that the COVID-19 pandemic will pose 
severe challenges to programmes that supply the key 
interventions responsible for reducing malaria morbidity 
and mortality. In this study, we provide an evaluation of 
these effects under a plausible range of scenarios. A key 
assumption of this research is that malaria morbidity 
and mortality are not directly affected by COVID-19 
infection, as it is currently unknown what effects co-
infection with malaria will have on either disease.
In our worst-case scenario, in which mass ITN 
distributions are cancelled and there are 75% reductions in 
routine ITN distribution and effective treatment of cases 
with an antimalarial, the incidence of malaria in 2020 
would increase by 21·5% (95% UI 16·3–27·9), or 46·4 
(35·0–60·0) million cases, relative to the mean baseline 
level across malaria-endemic African countries. Further-
more, in this scenario, malaria-attributable deaths would 
nearly double, from 386·4 (307·8–497·8) thousand to 
768·6 (586·1–1038·7) thousand. The large increase in 
deaths is a result of the crucial role of antimalarial drugs in 
preventing progression to death in malaria-infected 
individuals. As such, if COVID-19 outbreaks lead to 
fewer malaria cases being effectively treated, whether 
through shifts in public health policy or altered individual 
behaviours, we predict a large increase in malaria mortality. 
This accentuated role of antimalarial drugs in our approach 
stems from our application of the case fatality rate to only 
untreated cases, meaning we assume that cases left 
untreated result in a proportionate increase in deaths. 
Alternate assessments of the effect of COVID-19 on 
malaria in Africa29 that arrived at a contradictory conclusion 
did not use this assumption.
The smaller effect of decreasing ITN distributions, as 
opposed to decreasing antimalarial drugs, on malaria 
incidence differs from previous research that showed ITNs 
to be largely responsible for driving down malaria in Africa 
since 2000.7 This difference is interpretable as an effect of 
the existing stock of ITNs held by households continuing 
to provide effective, albeit waning, protection against 
malaria transmission. Our modelled ITN esti mates, which 
predict waning coverage rather than a dramatic drop, 
differ from those used to derive alternate assessments of 
malaria incidence in Africa in 2020.29 By comparing 
results between countries, our analysis also suggests that 
disruptions to mass ITN distribution campaigns will have 
a larger effect on malaria than disruptions in routine 
ITN distributions, which reflects the larger role of mass 
campaigns in maintaining coverage. Furthermore, if 
COVID-19 causes a widespread decline in ITN distributions 
in 2020, the full impact of increased malaria incidence will 
not be realised until future years.
The effects of COVID-19 on malaria vary widely 
between nations, and are driven by each country’s 
epidemiological context, size, and current intervention 
coverage status. In Guinea-Bissau, for example, we 
predict an increase of 217·8 (110·5–318·7) thousand in 
the number of cases in the worst-case scenario, which 
reflects the role of ITNs and antimalarial drugs in 
decreasing interventions in this nation. This pattern 
is repeated elsewhere and is intuitive, with countries 
planning ITN mass campaigns in 2020 attributing a 
greater proportion of their increased cases to ITNs than 
countries that had recent mass ITN distributions. 
Similarly, malaria-endemic countries that have high 
coverage of antimalarial drugs in the absence of 
COVID-19-related disruptions will have larger increases 
in cases and deaths within our hypothetical scenarios. 
Unsurprisingly, the largest absolute effects are predicted 
Figure 5: Effect of cancellation of mass distribution campaigns on 
ITN coverage
Shown, for the 24 countries with scheduled mass campaigns in 2020, are 
estimated ITN coverage rates in two scenarios: one in which all 2020 mass 
and routine distribution campaigns continue as planned (the baseline scenario) 
and the other in which mass campaigns are cancelled, showing the difference in 
expected coverage rates due to the suspension of mass campaigns alone. 
Details of the size of the mass campaigns planned in 2020 for each country are 
shown in the appendix (p 1). BEN=Benin. CMR=Cameroon. CAF=Central African 
Republic. TCD=Chad. CIV=Côte d’Ivoire. COD=Democratic Republic of the Congo. 
ERI=Eritrea. ETH=Ethiopia. GNB=Guinea-Bissau. ITN=insecticide-treated net. 
KEN=Kenya. MLI=Mali. MRT=Mauritania. MOZ=Mozambique. NER=Niger. 
NGA=Nigeria. RWA=Rwanda. SLE=Sierra Leone. SOM=Somalia. 
SSD=South Sudan. SDN=Sudan. TZA=Tanzania. TGO=Togo. UGA=Uganda. 
ZMB=Zambia.
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in the countries with the greatest malaria burden, such 
as Nigeria and DR Congo, which have large populations 
and high environmental suitability for malaria trans-
mission. In the most extreme scenario, Nigeria would 
have estimated increases of 10·1 (7·3–13·0) million cases 
and 96·5 (87·7–105·1) thousand deaths, and DR Congo 
would have increases of 3·8 (2·2–6·2) million cases and 
43·8 (39·4–50·7) thousand deaths.
Any forward-looking analysis relies on multiple 
assumptions and simplifications. For example, we were 
unable to robustly estimate the proportion of patients 
with severe malaria who would receive effective 
inpatient care under normal circumstances, nor how 
hospital-based case management would be affected 
during this pandemic. As such, we focused our case-
management scenarios on the effects on front-line 
treatment of uncomplicated cases with antimalarial 
drugs, but assumed that case fatality rates among 
untreated patients would remain unchanged. This 
assumption is probably a conservative one, because the 
survival rates of patients with severe malaria are likely 
to decline, further adding to the effects on mortality. 
Another important limitation of this research is that we 
do not address other malaria control interventions, such 
as intermittent or seasonal preventive treatment with 
chemoprophylaxis or indoor spraying of long-lasting 
insecticidal residues. Although these interventions are 
important in some contexts, their application is highly 
localised and thus their importance at continental or 
national scales is typically secondary to that of ITNs and 
antimalarial drugs. Likewise, we did not consider novel 
mitigation measures that might emerge in response to 
this crisis. For example, official guidelines now advocate 
a range of practical measures that malaria programmes 
can undertake to attempt to reduce surges in malaria 
burden.30 Lastly, this analysis ignores existing national 
plans to use risk-stratification strategies for optimising 
the control and treatment of malaria based on the level 
of burden. Such strategies could mitigate the increases 
we estimated by main taining ITN and antimalarial 
drug coverage in areas with high levels of endemic 
malaria if supplies of these commodities became 
limited.
The COVID-19 pandemic has exerted enormous 
pressure on health systems in well resourced, high-
income nations worldwide. Although many malaria-
endemic African nations have shown remarkable 
resilience and adaptivity in the face of previous global 
health threats,31 they nevertheless face the unprecedented 
challenge of COVID-19 with a comparatively lower health-
care system capacity and a higher baseline level of malaria 
burden. Our analysis suggests that the direct response to 
COVID-19 must be integrated with efforts to ensure 
malaria control is maintained. Failure to do so risks 
amplifying the mortality caused by this pandemic, 
especially in children, and reversing of one of the most 
impactful public health campaigns of the past two decades.
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